UCB SA (EBR:UCB)
Belgium · Delayed Price · Currency is EUR | Market Cap | 53.65B +20.0% |
| Revenue (ttm) | 8.52B +24.5% |
| Net Income | 2.19B +64.7% |
| EPS | 11.32 +64.9% |
| Shares Out | 190.66M |
| PE Ratio | 24.86 |
| Forward PE | 20.69 |
| Dividend | 1.45 (0.52%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 279,985 |
| Open | 281.70 |
| Previous Close | 280.00 |
| Day's Range | 279.90 - 283.20 |
| 52-Week Range | 197.45 - 289.50 |
| Beta | 0.19 |
| Analysts | Buy |
| Price Target | 291.58 (+3.62%) |
| Earnings Date | Feb 25, 2027 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]
Financial Performance
In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for UCB stock is "Buy." The 12-month stock price target is €291.58, which is an increase of 3.62% from the latest price.
News
Best Income Stocks to Buy for October 22nd
BBCP, ATLO and UCB made it to the Zacks Rank #1 (Strong Buy) income stocks list on October 22, 2026.
United Community Banks (UCB) Q3 2026 Earnings Call Transcript
Operating EPS rose to $0.77 as core loan growth accelerated to 10% annualized.
United Community Banks (UCB) Q3 Earnings Match Estimates
United Community Banks (UCB) delivered earnings and revenue surprises of 0.00% and +25.98%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the sto...
FDA Approves New Self-Injection Option For UCB's ZILBRYSQ In Generalized Myasthenia Gravis
(RTTNews) - UCB (UCBJY) announced that the U.S. FDA has approved a self-administered autoinjector option for ZILBRYSQ (zilucoplan) for adults with generalized myasthenia gravis (gMG) who are anti-acet...
United Community Banks (UCB) Q3 2026 Preview: EPS Est. $0.77, Reports October 20
Wall Street expects modest growth from United Community Banks when the regional lender reports third-quarter 2026 results before the bell on October 20th. T... The post United Community Banks (UCB) Q3...
UCB Dedicates Site for New U.S. Biologics Manufacturing Campus in Georgia
Site dedication signals continued momentum for UCB's first U.S. manufacturing campus Emphasizes long-term commitment to advancing innovation, patient access, and workforce development in Gwinnett Coun...
Why United Community Banks (UCB) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does United Community Banks (UCB) have what it takes? Let's find out.
UCB SA Transcript: Investor update
BIMZELX continues to gain global traction, especially in HS, with robust long-term data supporting its efficacy and safety. Early and first-line use leads to superior outcomes, and quality of life improvements are significant. Access is expanding, and while new oral therapies are emerging, injectables remain preferred due to efficacy.
UCB SA Slides: Investor update
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
UCB SA Transcript: J.P. Morgan European Healthcare CEO Call Series
A decade of growth is underway, fueled by strong execution, strategic acquisitions, and innovation in immunology and neurology. BIMZELX leads with unique efficacy and expanding access, while the pipeline advances in atopic dermatitis, severe epilepsy, and T-cell engager therapies.
UCB SA Transcript: Bank of America Global Healthcare Conference
The session highlighted robust H1 growth, upgraded guidance, and a focus on long-term innovation. BIMZELX remains the primary growth driver, with expanding indications and strong access strategies. Early-stage pipeline assets and targeted commercial execution underpin confidence in sustained growth and margin expansion.
UCB upgraded to Hold from Underperform at Jefferies
Jefferies upgraded UCB (UCBJF) to Hold from Underperform with a price target of EUR 220, up from EUR 212. The firm says its sell thesis has played out while UCB’s…
UCB SA Earnings Call Transcript: H1 2026
First-half 2026 saw net sales rise 23% to EUR 4.1 billion, driven by five growth products now over half of revenue. Upgraded guidance reflects strong BIMZELX momentum, new peak sales target above EUR 7 billion, and robust pipeline expansion through acquisitions and clinical advances.
UCB SA Earnings release: H1 2026
UCB SA released its H1 2026 earnings on July 30, 2026, summarizing the period's financial results.
UCB SA Quarterly report: H1 2026
UCB SA has published its H1 2026 quarterly earnings report on July 30, 2026.
UCB SA Slides: H1 2026
UCB SA has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 30, 2026.
UCB shares fall despite guidance upgrade as investors question earnings quality
Belgian biopharmaceutical group UCB raised its 2026 earnings guidance on Thursday, but its shares fell more than 8% as investors focused on weaker-than-expected sales of flagship drug Bimzelx and qu...
UCB price target raised to EUR 305 from EUR 290 at Berenberg
Berenberg analyst Kerry Holford raised the firm’s price target on UCB (UCBJF) to EUR 305 from EUR 290 and keeps a Buy rating on the shares.
UCB downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Charles Pitman-King downgraded UCB (UCBJF) to Equal Weight from Overweight with a price target of EUR 300, down from EUR 310. The firm cites the company’s growth investments…
UCB SA Transcript: Investor update
BE BOLD demonstrated bimekizumab's statistically significant superiority over risankizumab in joint outcomes for psoriatic arthritis, with sustained efficacy and a safety profile consistent with prior studies. The results are expected to influence clinical guidelines, prescribing practices, and payer dynamics, supporting bimekizumab's positioning as a first-line therapy.
UCB SA Slides: Investor update
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Cullinan jumps after UCB acquires Candid Therapeutics
Shares of Cullinan Therapeutics (CGEM) are moving higher after UCB (UCBJF) announced an agreement to acquire privately held Candid Therapeutics. Cizutamig, Candid’s lead investigational asset, is “pos...
UCB to Buy Candid Therapeutics for Up to $2.2 Billion
The deal seeks to bolster the company's pipeline of experimental treatments for autoimmune and inflammatory diseases.
Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion
Belgian biopharmaceuticals company UCB has agreed to buy privately-held Candid Therapeutics in a deal worth up to $2.2 billion, the companies said on Sunday.
UCB SA Slides: Acquisition presentation
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on May 3, 2026.